Bluebird Bio and Celgene Reports Results of bb21217 in P-I (CRB-402) study for 3L+ r/r Multiple Myeloma
Shots:
- The P-I CRB-402 study involves assessing of bb21217 as an investigational anti- BCMA CAR T (150 x 106) cell therapy in patients with r/r multiple myeloma
- The study demonstrated 83% of total patients (N=12) achieved an objective clinical response; CR 3- VGPR 2; 4 PR; with no death occurred
- bb21217 is an anti-BCMA CAR T cell therapy targeted to kill plasma & myeloma cells expressing B cell maturation antigen (BCMA) and is jointly developed by Bluebird Bio and Celgene
Ref: Bluebird Bio | Image: Wral Techwire
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com